Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin.
Gorodnova TV, Sokolenko AP, Kotiv KB, Sokolova TN, Ivantsov AO, Guseynov KD, Nekrasova EA, Smirnova OA, Berlev IV, Imyanitov EN.
Gorodnova TV, et al.
Hered Cancer Clin Pract. 2021 Feb 3;19(1):14. doi: 10.1186/s13053-021-00173-2.
Hered Cancer Clin Pract. 2021.
PMID: 33536037
Free PMC article.
The comparator group included 16 women, who received standard NACT combination of paclitaxel 175 mg/m(2) and carboplatin (6 AUC), given every 3 weeks (TCbP scheme). RESULTS: None of the patients treated by the MAP scheme demonstrated complete pathologic response in ovaries …
The comparator group included 16 women, who received standard NACT combination of paclitaxel 175 mg/m(2) and carboplatin (6 AUC), given ever …